RDEA-594 sodiuM

RDEA-594 sodiuM - Names and Identifiers

Name	RDEA-594 sodiuM
Synonyms	CS-651 RDEA-594 sodiuM LESINURAD SODIUM Lesinurad sodiuM Pentanedioicacid,5-oxo-,diethylester sodium 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetate Sodium 2-((5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3- yl)sulfanyl)acetate Acetic acid, 2-((5-bromo-4-(4-cyclopropyl-1-naphthalenyl)-4H-1,2,4-triazol-3-yl)thio)-, sodium salt
CAS	1151516-14-1

RDEA-594 sodiuM - Physico-chemical Properties

Molecular Formula	C17H13BrN3O2S.Na
Molar Mass	426.26279
Solubility	DMSO: ≥ 26 mg/mL mother liquor preservation: sub-package and freeze storage to avoid repeated freezing and thawing;-20 ℃,1 month;-80 ℃,6 months (after dilution, the solution temperature is low and storage may precipitate, as far as possible to use the current preparation) Cell experiment: dissolve with DMSO first: dilute with culture medium then, and the dilution process is recommended to be carried out in stages to avoid too fast concentration change leading to compound precipitation. If the compound is precipitated during the dilution process, it can be redissolved by ultrasound. During dilution, ensure that the final concentration of DMSO in the working fluid should be below 0.1% as far as possible, and the maximum should not exceed 0.5%, and set up a DMSO control group with corresponding concentration. Animal experiment: Dissolve with DMSO first: dilute with water or normal saline, etc. The dilution process is recommended to be carried out in sections to avoid excessive concentrat
Storage Condition	-20℃
Target	Km: 0.85 µM (OAT1), 2 µM (OAT3)

RDEA-594 sodiuM - Upstream Downstream Industry

Raw Materials

4-(4-cyclopropylnaphthalen-1-yl)-1H-1,2,4-triazole-5(4H)-thione
1-Cyclopropyl-4-nitronaphthalene
1-aMino-4-cyclopropylnaphthalene oxalate
N-(4-Cyclopropyl-1-naphthalenyl)-2-formylhydrazinecarbothioamide
TERT-BUTYL 4-CYCLOPROPYLNAPHTHALEN-1-YLCARBAMATE
1-Naphthalenamine, 4-cyclopropyl-
lesinurad int
NAPHTHALENE, 1-CYCLOPROPYL-4-ISOTHIOCYANATO-
1-cyclopropylnaphthalene
4-cyclopropylnaphthalen-1-aMine hydrochloride
1-Bromonaphthalene

RDEA-594 sodiuM - Reference

Reference

1: LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. Available from http://www.ncbi.nlm.nih.gov/books/NBK547982/ PubMed PMID: 31643315.
2: Pérez-Ruiz F, Jansen T, Tausche AK, Juárez-Campo M, Gurunath RK, Richette P. Efficacy and safety of lesinurad for the treatment of hyperuricemia in gout. Drugs Context. 2019 May 29;8:212581. doi: 10.7573/dic.212581. eCollection 2019. Review. PubMed PMID: 31191704; PubMed Central PMCID: PMC6544139.
3: Dean L. Lesinurad Therapy and CYP2C9 Genotype. 2019 Feb 11. In: Pratt V, McLeod H, Rubinstein W, Dean L, Kattman B, Malheiro A, editors. Medical Genetics Summaries [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2012-. Available from http://www.ncbi.nlm.nih.gov/books/NBK537366/ PubMed PMID: 30742400.
4: Jansen TL, Perez-Ruiz F, Tausche AK, Richette P. International position paper on the appropriate use of uricosurics with the introduction of lesinurad. Clin Rheumatol. 2018 Dec;37(12):3159-3165. doi: 10.1007/s10067-018-4306-9. Epub 2018 Sep 22. Review. PubMed PMID: 30244431.
5: Claus LW, Saseen JJ. Patient considerations in the management of gout and role of combination treatment with lesinurad. Patient Relat Outcome Meas. 2018 Jul 18;9:231-238. doi: 10.2147/PROM.S108868. eCollection 2018. Review. PubMed PMID: 30140163; PubMed Central PMCID: PMC6054769.
6: On PC. Lesinurad (Zurampic) for Gout. Am Fam P